sumatriptan has been researched along with lu 208075 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Higa, A; Hoshi, H; Imai, JI; Ito, E; Morisawa, G; Takagi, M; Watanabe, S; Yanagisawa, Y | 1 |
1 review(s) available for sumatriptan and lu 208075
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for sumatriptan and lu 208075
| Article | Year |
|---|---|
Evaluation system for arrhythmogenic potential of drugs using human-induced pluripotent stem cell-derived cardiomyocytes and gene expression analysis.
Topics: Amlodipine; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; Bisoprolol; Cardiotoxicity; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gene Expression Profiling; Gene Expression Regulation; Humans; Induced Pluripotent Stem Cells; Linagliptin; Long QT Syndrome; Myocytes, Cardiac; Naphthalenes; Phenylpropionates; Piperazines; Prasugrel Hydrochloride; Pyridazines; Sumatriptan; Tetrazoles; Transcriptome; Up-Regulation | 2017 |